<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292146</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000529</org_study_id>
    <nct_id>NCT03292146</nct_id>
  </id_info>
  <brief_title>Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study</brief_title>
  <official_title>Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to
      investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators
      hypothesize that 12 months of denosumab administration will result in an increase in bone
      mineral density, decrease in markers of bone resorption and improvement in bone
      microarchitecture in osteopenic women with anorexia nervosa compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone density</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Change in bone density</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bone Density</condition>
  <condition>Bone Loss</condition>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorder</condition>
  <condition>Atypical Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg injection at baseline study visit and 6 month study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection at baseline study visit and 6 month study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 MG [Prolia]</intervention_name>
    <description>Denosumab 60mg injection at baseline and 6 months</description>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>Placebo Injection at baseline and 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

        Inclusion Criteria:

          -  Female

          -  Age 20-60 years, skeletally mature with closed epiphyses

          -  Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria

          -  BMD T-score &lt; -1.0

          -  Normal serum 25-OH vitamin D (&gt;30 ng/mL) and calcium levels

          -  For women of reproductive age, agree to use an effective contraceptive method. Highly
             effective methods of birth control include:

               -  Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or
                  skin patch)

               -  Intrauterine device (IUD)

               -  Intraduterine hormonal-releasing system (IUS)

               -  Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)

               -  Your male partner has had a vasectomy and testing shows there is no sperm in the
                  semen

          -  Dental check up within the past year

        Exclusion Criteria:

          -  Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's
             or renal failure

          -  Subjects with a known esophageal disease cannot participate in the alendronate
             extension study

          -  Any medication known to affect bone metabolism within 3 months of the study, excluding
             oral contraceptives or other forms of estrogen administration. Bisphosphonates must
             have been discontinued for at least one year before participation

          -  Immunodeficiency or taking immunosuppressive therapy

          -  Serum potassium &lt;3.0 meq/L

          -  Serum ALT &gt;3 times upper limit of normal

          -  eGFR of less than 30 ml/min

          -  Hypocalcemia

          -  Diabetes mellitus

          -  Active substance abuse, including alcohol

          -  History of malignancy

          -  Paget disease of bone

          -  Osteomalacia

          -  Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental
             procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months),
             poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of
             corticosteroids.

          -  Planned invasive dental procedure over the next 24 months.

          -  Known senstivity to any of the products or components to be administered during dosing
             or known sensitivity to mammalian cell derived drug products

          -  Sensitivity to calcium or vitamin D supplements

          -  Pregnant, planning to become pregnant with 7 months after the end of treatment and/or
             breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

